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Abstract: Early diagnosis of disease and follow-up of therapy is of vital importance for appropriate
patient management since it allows rapid treatment, thereby reducing mortality and improving
health and quality of life with lower expenditure for health care systems. New approaches include
nanomedicine-based diagnosis combined with therapy. Nanoparticles (NPs), as contrast agents
for in vivo diagnosis, have the advantage of combining several imaging agents that are visible
using different modalities, thereby achieving high spatial resolution, high sensitivity, high specificity,
morphological, and functional information. In this work, we present the development of aluminum
hydroxide nanostructures embedded with polyacrylic acid (PAA) coated iron oxide superparamagnetic
nanoparticles, Fe3O4@Al(OH)3, synthesized by a two-step co-precipitation and forced hydrolysis
method, their physicochemical characterization and first biomedical studies as dual magnetic resonance
imaging (MRI)/positron emission tomography (PET) contrast agents for cell imaging. The so-prepared
NPs are size-controlled, with diameters below 250 nm, completely and homogeneously coated with an
Al(OH)3 phase over the magnetite cores, superparamagnetic with high saturation magnetization value
(Ms = 63 emu/g-Fe3O4), and porous at the surface with a chemical affinity for fluoride ion adsorption.
The suitability as MRI and PET contrast agents was tested showing high transversal relaxivity (r2)
(83.6 mM−1 s−1) and rapid uptake of 18F-labeled fluoride ions as a PET tracer. The loading stability
with 18F-fluoride was tested in longitudinal experiments using water, buffer, and cell culture media.
Even though the stability of the 18F-label varied, it remained stable under all conditions. A first in vivo
experiment indicates the suitability of Fe3O4@Al(OH)3 nanoparticles as a dual contrast agent for
sensitive short-term (PET) and high-resolution long-term imaging (MRI).
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1. Introduction
Advances in physics and engineering have allowed the development of non-invasive imaging
techniques that gave rise to a striking medical revolution in which detailed physiology, pathology, and
functionality of the human body could be revealed with detailed precision non-invasively. Among
others, X-ray, magnetic resonance imaging (MRI), and positron emission tomography (PET), have
settled in as the core technologies that constitute a milestone in medical practice [1,2].
In the quest for increasing the potential of these imaging techniques, nuclides used as contrast
agents like Gd, 18F, 68Ga [3] have become a crucial tool for revealing subtle differences between tissues
allowing for enhanced accuracy of diagnosis and assessment of the effectiveness of therapies in the
last decades.
With the appearance of dual imaging modalities (PET/MRI, PET/computed tomography (CT), and
single-photon emission computed tomography (SPECT)/CT), there is not only a potential for further
improved diagnosis but also a continuous need for developing more versatile and less harmful contrast
agents, capable to provide multimodal contrast in a single formulation, robust effectiveness under
minimal dosages, negligible secondary effects, and stable performance for long-term follow-up using
functional diagnosis procedures [4–8].
Compared to the conventional use of small molecules as contrast agents for in vivo and in vitro
imaging, nanomaterials offer significant advantages and are providing important contributions to the
field of diagnostic and non-invasive molecular imaging, which includes the generation of stronger and
long-lasting contrast and the combination with therapy delivery in theranostic agents [9,10].
Recently, magnetite iron oxide nanoparticles (Fe3O4 NPs) have attracted considerable interest as
negative MRI contrast agents due to their excellent magnetic properties, low toxicity, biocompatibility, and
biodegradability compared to the other magnetic NPs (MnFe2O4, ZnFe2O4, CoFe2O4, etc.) [11]. For this
application, Fe3O4 nanoparticles with a narrow size distribution, superparamagnetic behavior, and
specific surface modification are desired [12,13]. This surface modification can increase the properties
of biocompatibility and avoid the agglomeration of the bare particles due to the magnetostatics
interaction [14]. Many materials and coating approaches have been utilized for modifying the surface
of these nanoparticles. Polymers are the most widely used coating materials and can be classified as
hydrophilic or amphiphilic, neutral or charged, and homopolymers or copolymers. Amongst them,
coating with polyethylene glycol (PEG), Dextran, or polyacrylic acid [14–16] has been widely used. Also,
to avoid desorption of the polymeric coating by heating or dilution, one or more functional groups, such
as carbonate or phosphonate, are necessary to bind with the NPs. Therefore, the use of an inorganic
shell material that introduces stability, functionality, and water-solubility is desirable.
Their versatile performance has already given rise and excellent T2/T2* contrast for MRI providing
high-resolution images for in vivo cell tracking [17,18] and clinically tested and approved formulations
for commercialization as contrast agents for MRI (Feridex; Resovist, Ferumoxtran-10) [19], or as
therapeutic agents in magnetic hyperthermia therapies for brain tumor treatment (NanoTherm) [14,20].
However, one disadvantage of the T2/T2* MR contrast generated by superparamagnetic (SPM)
iron oxide NPs is that this hypointense signal change (darkening) is not suitable for imaging against
a hypointense background like it is the case in MR images of the lungs or parts of the abdomen.
In addition, MRI lacks the high sensitivity of imaging techniques like PET. Therefore, contrast agents
that generate dual contrast for MRI and PET can help to overcome the limitations of individual imaging
techniques [21,22]. SPM nanoparticles, with an engineered composition, offer a platform to incorporate
different components into one single entity. Specifically, dual PET/MRI contrast agents could be
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obtained combining a magnetite core (Fe3O4) for MRI contrast embedded in an aluminum hydroxide
shell (Al(OH)3), which can be labeled with 18F-fluoride ions as a PET tracer [23,24].
In the present work, we have developed hydrophilic and colloidally stable Fe3O4@Al(OH)3
nanostructures, with almost spherical homogeneous size-morphology, to be used as dual MRI/PET
contrast agents, by a relatively simple and controllable chemistry method [25–28]. Magnetite cores
with good crystalline quality, SPM response, T2 contrast, and controlled size, were prepared by a
co-precipitation method, based on mild starting reagents and low temperatures, suitable for scaling up
purposes. Colloidal stability [29] was ensured by adding a layer of polyacrylic acid (PAA), which was
selected for its strong coordination of carboxylate groups with iron cations on the magnetite surface and
their high degree of dispersibility in water [30,31]. Al(OH)3 external coating shell was incorporated by a
forced hydrolysis procedure, providing the nanostructure with a porous and positively charged surface
with an affinity for fluoride ions to be used in PET imaging. This approach was tested for in vitro
mesenchymal stem cell (MSC) labeling, and cytotoxicity assessment of the NPs for future cell tracking
applications. The visualization of cells was demonstrated in vivo in a preliminary PET/MRI experiment.
2. Materials and Methods
2.1. Chemicals and Synthesis
2.1.1. Chemicals
Chemicals used for this study were, aluminum nitrate nonahydrate (Al(NO3)3·9H2O, 98%),
aluminum sulfate hexadecahydrate (Al2(SO4)3·16H2O, 98%), iron(III) chloride hexahydrate (FeCl3·6H2O,
99%), iron(II) sulfate heptahydrate (FeSO4·7H2O, 99%), hydrochloric acid (HCl, 37%), nitric acid (HNO3,
65%), ammonium hydroxide (NH4OH, 28%), sodium fluoride (NaF, ≥99%), polyacrylic acid ((C3H4O2)n
average Mw 1800), urea (CON2H4, 98%) and agar all obtained from Sigma-Aldrich (St. Louis, MO, USA).
Total Ionic Strength Adjustment Buffer solution (TISAB III), phosphate-buffered saline (PBS), TrypLE,
high-glucose Dulbecco’s Modified Eagle’s Medium (DMEM) containing GlutaMax, fetal bovine serum
(FBS), and penicillin-streptomycin were obtained from Gibco-Invitrogen (Gibco-Invitrogen™-Fisher,
Carlsbad, CA, USA), Milli-Q (Millipore®, Burlington, MA, USA) deionized water was used in all
the experiments.
2.1.2. Synthesis of Fe3O4 NPs Functionalized with PAA
MNPs were obtained by co-precipitation, following Massart’s method [32] with some modifications.
In a typical synthesis, FeCl3•6H2O (45 mmol) and FeSO4•7H2O (30 mmol) were dissolved in 100 mL of
10 mM HCl aqueous solution with mechanically stirring. The mixture was heated at 60 ◦C, then NH4OH
(770 mmol) and PAA (1.11 mmol) were added, and the reaction was carried out for 1 h. After that, the
obtained magnetic nanoparticles were acidified up to pH 5 with the incorporation of the HCl solution at
9%. Magnetite NPs were separated from the reaction medium by a magnetic field and washed several
times (6×) with Milli-Q water. Finally, Fe3O4@PAA NPs were re-dispersed in Milli-Q water. The total
solid content was determined by thermogravimetric analysis (TGA): Wmag = 5.5% by weight.
2.1.3. Synthesis of Functionalized Fe3O4 NPs with PAA Coated Then by a Layer of Al(OH)3
Al(OH)3 coating on the Fe3O4@PAA NPs was prepared by a forced chemical hydrolysis method
as reported by Roh et al. [33] with some alterations. Briefly, 200 mg magnetite coated with PAA
nanoparticles were added in 250 mL Milli-Q water, after sonication for 15 min to form a homogenous
solution, Al(NO3)3·9H2O (11.6 mmol), Al2(SO4)3·16H2O (1.92 mmol), and urea (0.5 mol) were added.
The reactant solution was added in an oil bath of 98 ◦C, with mechanical stirring for 1.5 h. The obtained
nanomaterial was magnetically separated, washed, and re-dispersed in Milli-Q water. The total solids
content was determined by TGA: Wmag = 2.46% by weight.
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2.2. Physicochemical Characterization
2.2.1. XRD-Structural Characterization
The characterization of the crystalline phases was performed by X-ray diffraction (XRD) with
powder samples using a Philips PW1710 diffractometer (Panalytical, Brighton, UK) with a Cu Kα
radiation source, λ = 1.54186Å. Measurements were collected in the 2θ angle range between 10◦ and
80◦ with steps of 0.02◦ and 10 s/step.
2.2.2. Microscopy Morphological Characterization
Morphology of the materials was characterized by scanning electron microscopy (SEM) using a
Zeiss FE-SEM ULTRA Plus (5 kV) microscope (Zeiss, Oberkochen, Germany). Transmission electron
microscopy (TEM) was realized with High-Resolution Transmission Electron Microscopy LIBRA 200FE
with field-emission gun and OMEGA Energy Filter (Carl Zeiss NTS GmbH, Oberkochen, Germany).
The TEM measurements were performed at 200 kV and the High-Angle Annular Dark Field (HAADF).
Scanning transmission electron microscopy (STEM) images were performed using a HAADF detector
in STEM mode, and Z-contrast differences were visualized. The dispersive energy analyses were
performed with an Oxford energy dispersive X-ray (EDX) detector.
2.2.3. Surface Chemistry Characterization
Fourier transform infrared (FTIR) spectra of the surface functional groups of the nanostructures
were recorded with a Thermo Nicolet Nexus spectrometer (Thermo Fisher Scientific, Madrid, Spain)
using the attenuated total reflectance (ATR) method from 4000 to 400 cm−1.
2.2.4. Compositional Characterization
Iron content in the nanocomposite samples was determined by flame atomic absorption
spectroscopy (FAAS) performed with an Atomic Absorption Spectrometer (Perkin Elmer 3110, Perkin,
Waltham, MA, USA).
The composition of the samples was analyzed with a TGA Perkin Elmer model 7 (Perkin, Waltham,
MA, USA).
The adsorption percentage of non-radioactive fluoride was determined using a pH & Ion-Meter
BASIC 20+ (CRISON, Barcelona, Spain).
2.2.5. Magnetic Characterization
Direct current (DC) magnetization curves of dried samples were measured using a vibrating
sample magnetometer (VSM) (DMS, Lowell, MA, USA). In such a device, the measurement of magnetic
hysteresis loops at room temperature was carried out under external magnetic fields from −10 to
10 kOe.
2.2.6. Preliminary Study of Non-Radioactive 19F Adsorption
The adsorption capacity of Fe3O4@Al(OH)3 NPs of fluoride ions (non-radioactive 19F) was
assessed with the help of an ion-selective electrode (ISE) method, using as working and reference
electrodes fluoride and silver, respectively. For this purpose, from an initially prepared solution of NaF
(1 g/L), a set of 25 solutions were prepared by mixing 10 mL of aliquots with defined concentrations
(from 20 to 500 mg/L) with 10 mg of Fe3O4@Al(OH)3 NPs at pH 6.5. The mixtures were incubated at
25 ◦C during 10 h at 250 rpm with orbital stirring to facilitate the adsorption of fluoride ions on the
aluminum hydroxide shell. Afterward, the magnetic nanostructures (Fe3O4@Al(OH)3) were separated
from the solution with a neodymium magnet (NdFeB), and the supernatants were collected for ISE
analysis. As in a typical experiment, 5 mL of supernatant was mixed with 25 mL of Total Ionic Strength
Adjustment Buffer solution (TISAB III) to avoid interference of Al(III) and Fe(III) with the electrodes.
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In this way, metal ions form stable complexes by reacting with 1,2-Cyclohexylenedinitrilotetraacetic
acid (buffer component), and fluoride ions are free and available for their concentration analysis based
on pH and ion-meter with an ISE of fluoride and silver.
2.2.7. Labeling of Fe3O4@Al(OH)3 Nanoparticles with 18F-Sodium Fluoride
Fifty µL containing 5 to 7 MBq [18F]NaF were added to tubes containing 1, 2, 5, or 10 mg
of Fe3O4@Al(OH)3 NPs in 500 µL of water. Tubes were continuously shaken for 15 min at room
temperature. This was followed by separation of the nanoparticles by either centrifugation (3000 rpm
for 20 min) or by magnetic separation using a permanent magnet and then were washed three times
with water. The radioactivity of the particles and supernatants were measured after each washing step
using a gamma counter. All measurements were performed in triplicates.
2.2.8. [18F]NaF Production
Fluorine-18 was produced by irradiation of H218O with 18-MeV protons using a cyclotron (IBA
Cyclone 18/9, IBA, Louvain-la-Neuve, Belgium). [18F]F− was separated from [18O]H2O by trapping
on a Sep-Pak Light Accell plus QMA anion exchange cartridge (Cl− form; Waters, Zellik, Belgium).
The cartridge was washed with water (3 mL, HPCE grade; Sigma-Aldrich, Overijse, Belgium) and
[18F]F− was eluted from the cartridge with an aqueous solution of sodium chloride 0.9% (Mini-Plasco,
solution for injection, B. Braun, Diegem, Belgium) to obtain a concentration of 0.8–3.0 GBq/mL at the
end of synthesis.
2.2.9. Radiolabeling of Fe3O4@Al(OH)3 NPs
To evaluate the time course of radiolabeling, 45 µL of Fe3O4@Al(OH)3 NPs containing 60 µg of Fe
were incubated with 5–30 MBq [18F]NaF (5–30 µL) while shaking. Two, five, and 10 min after labeling,
2 µL samples were taken and blotted on instant thin layer chromatography (iTLC) papers impregnated
with silica gel (iTLC-SG papers; Varian, Diegem, Belgium). The papers were developed in an elution
chamber using NaCl 0.9% as the mobile phase. The read-out was performed using a 2480 Wizard2
Automatic Gamma Counter (20 s protocol; PerkinElmer, Waltham, MA, USA) after splitting the papers
into two equal halves representing the unbound and bound radiotracer. In addition, autoradiography
was performed using phosphor screens (Perkin Elmer) in standard film cassettes. The screens were
removed from the cassettes after a five-minute exposure and were scanned immediately at 300 dpi
resolution using a Cyclone Plus System (Perkin Elmer). Images were analyzed using the manufactures’
Optiquant software (version 5; Perkin Elmer).
For further in vitro and in vivo experiment, NPs are labeled with [18F]NaF for ten minutes in
Milli-Q water. Afterward, they are centrifuged for 20 min at 4000 rpm and resuspended in the media
of choice for further application.
2.2.10. Stability of the Radiolabeling
The adsorption stability of [18F]F− to the Fe3O4@Al(OH)3 NPs was evaluated after centrifugation
(20 min at 4000 rpm) of the NPs (11.85 µg iron, labeled with 5 MBq [18F]NaF). The supernatant was
removed and the labeled NPs were resuspended in 500 µL of one of the following media: (1) Milli-Q
water, (2) saline (sodium chloride 0.9%), (3) PBS, (4) TrypLE, (5) high-glucose DMEM containing
GlutaMax and 15% FBS, (6) 50% DMEM + GlutaMax and 50% FBS, or (7) FBS. All components used
in conditions (3)–(7) were obtained from Gibco (ThermoFisher Scientific, Erembodegem, Belgium).
Afterward, NPs were exposed to the media for 30 min, 1 h, 2 h, and 4 h at 37 ◦C. At the respective time
points, 2 µL samples were taken for iTLC.
In a second stability experiment, NPs were resuspended in either (1) Milli-Q, (2) high-glucose
DMEM containing GlutaMax, and 15% FBS, (3) 50% DMEM + GlutaMax, and 50% FBS or (4) FBS. NPs
were incubated for 15 min and centrifuged for 20 min at 4000 rpm. After the centrifugation step, the
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supernatant was removed, and 2 µL of the pellet consisting of NPs and 2 µL of the supernatant were
collected for iTLC measurements. Remaining NPs were then resuspended in a fresh medium. All steps
were repeated four times to determine.
iTLC was performed as described above. After splitting the iTLC papers into the bottom and top
halves (representing the nanoparticle and medium fraction), the radioactivity present on each half was
measured using a 20 s protocol on the gamma-counter. The percentage of the unbound and NP-bound
fraction of [18F]F− was calculated based on the total radioactivity present in the mixture.
2.2.11. Dual PET/MRI Scanning
PET/MR images were simultaneously acquired using a Bruker BioSpec 70/30 small animal
MRI scanner equipped with a PET insert (3 rings composed of eight monolithic lutetium-yttium
oxyorthosilicate (LYSO) crystals coupled to SiPMs; Bruker Biospin, Ettlingen, Germany) [34]. The MR
scanner with a horizontal bore of 30 cm was equipped with actively shielded gradients (200 mT m−1).
A quadrature radio-frequency resonator (transmit/receive; inner diameter 7.2 cm or 8.6 cm for in vivo and
in vitro scans, respectively; Bruker Biospin) was used for image acquisition. A one-hour static PET scan
and the following parametric MRI maps were simultaneously acquired in vitro: T2* (multigradient-echo
(MGE) with e echo time (TE) = 4–57.3 ms with 4.1 ms increments, repetition time (TR) = 7000 ms,
4 averages, matrix = 256 × 256), T2 (multi-slice multi-echo (MSME), TE = 14–280 ms with 14 ms
increments, TR = 5000 ms, 2 averages, matrix = 258 × 258) and T1 (spin-echo sequence with slice
selective inversion recovery, TE = 7.45 ms, recovery time = 10,000 ms, inversion times (TI) = 50–5500 ms
500, matrix = 128 × 128) maps. All in vitro scans have a field of view (FOV) 60 × 60 mm and contain
five slices of 1 mm thickness with a 1 mm gap between slices.
2.3. Biological Characterization
2.3.1. Cell Labelling Using Radiolabelled Fe3O4@Al(OH)3 NPs
Mouse mesenchymal stem cells (mMSCs) transduced with a lentiviral vector encoding for firefly
luciferase and the enhanced green fluorescent protein were cultured in high-glucose DMEM containing
GlutaMax supplemented with 15% FBS and 1% penicillin-streptomycin (Gibco). Cells were grown in a
humidified incubator at 37 ◦C, 21% O2, and 5% CO2 (Binder, Tuttlingen, Germany).
One day after mMSCs plating, cells were labeled with radiolabeled (RL) NPs (containing 0.38 mM
iron, diluted in saline) for 1 h. Next, the NP-containing saline was removed, cells were washed with
saline, and 0.5 mL TrypLE was added (approximately 5 min exposure) to detach the mMSCs from
the surface. Total cell count was performed using a Neubauer cell counting chamber (Hirschmann,
Eberstadt, Germany). Details on NP iron content and the amount of radioactivity are provided below.
2.3.2. Iron Content Measurement in Cell Labelling
To assess cell labeling stability, 100 µL of the sample (NPs or NP-labeled cells) was digested
with 100 µL of HNO3. Samples were diluted using distilled water to reach an exact volume of 5 mL.
The iron concentration was measured by inductively coupled plasma optical emission spectroscopy
(ICP-OES; using a Varian 720ES; Varian). The intensity of the emission at 238.204 nm was used for
iron quantification.
2.3.3. In Vitro PET/MR of RL Fe3O4@Al(OH)3 NPs and RL NP-Labelled mMSCs
Fe3O4@Al(OH)3 NPs containing 4.3 µg of iron were labeled with 10 MBq [18F]NaF, while 106
mMSC plated the day before where labeled with NPs containing 21.4 µg of iron in 1 mL of saline
(end concentration of iron on cells = 0.38 mM) and radiolabeled with 30 MBq [18F]NaF. For imaging
purposes, serial dilutions of these NPs and cells were resuspended in equal amounts of saline and
2% agar (microbiology grade; Sigma-Aldrich; diluted in distilled water) in 200 µL Eppendorf tubes.
The following controls were used: (1) equal amounts of saline and 2% agar, and (2) 5 × 104 unlabeled
mMSCs in saline and agar. The radioactivity present in the samples was measured using a dose
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calibrator (CRC-15 PET, Capintec Inc., Ramsey, NJ, USA). The tubes were then placed into a cylindrical
in-house made Teflon holder (outer diameter = 7 cm, inner diameter = 3.5 cm) filled with 2% liquid
agar. For more details on this phantom, see Trekker et al. [35]. After agar solidification, the phantom
was scanned using PET/MRI. Three MRI measurements were performed per phantom.
2.3.4. Image Analysis
MRI
All parametric maps, except T2* maps, were generated using the Paravision software (Bruker
Biospin, version 6.0.1). Due to the need for Eddy’s current correction, the following procedure was
used to generate the T2* maps: for each slice, the images for the TE 2–14 were co-registered to the
image of the first TE using the TurboReg plugin [36]. Afterward, parametric maps (exponential fitting)
were generated using an in-house written Python script. To quantify the T2*, T2, and T1 values of the
NPs/NP-labeled mMSCs, circular regions of interest were drawn within the images of Eppendorf tubes
on one slice of the scan.
PET
The manufacturer’s Albira software (Bruker Biospin) was used to reconstruct the acquired PET
scans. One-hour static scans were reconstructed using a maximum likelihood estimation method (MLEM;
parameters = 12 iterations, 0.5 mm isotropic resolution, decay/scatter/random correction). Reconstructed
PET images were analyzed in PMOD version 3.9 (PMOD Technologies, Zürich, Switzerland).
The PET scan was overlaid with the MR images using the PMOD FuseIT tool. Volumes of interest
were drawn around the contours of the Eppendorf tubes to quantify the radioactivity present in
each tube.
2.3.5. Cell Proliferation and Survival
Putative toxic effects due to the labeling procedure were performed by Trypan Blue exclusion
as a measure of cell viability/immediate cell death rates after overnight exposure (12 h) of MSCs to
different concentrations of Fe3O4@Al(OH)3 NPs. Long-term effects of the cell labeling with the iron
oxide contrast agents were studied after washing the cells and continued incubation of the cell lines in
iron-free medium and compared with unlabeled controls. Inhibition of proliferation was used as an
additional measure for potentially toxic effects. Hereby, population doubling times were determined
using t × ln (2)/ln (A/A0), where t is the time between two cell counts, A is the number of cells at the
end of the incubation, and A0 is the initial number of cells [37].
2.3.6. Statistical Analysis
All statistical analyses were performed in GraphPad Prism version 5.0.4 (GraphPad Software,
San Diego, CA, USA). Linear regressions of the relaxation rates (Rx) versus the iron concentration
present in the samples were used for determining the NPs/mMSCs relaxivities and relaxation rates.
Correlations between the number of NPs/cells and radioactivity were calculated using a Pearson’s
correlation test. Comparisons between the groups were analyzed using a one-way ANOVA with
Bonferroni correction. Comparisons between the groups at different time points were studied using a
two-way repeated-measures ANOVA or mixed-effect analysis in case of missing data with Bonferroni
correction for multiple comparisons. Differences were considered statistically significant when p < 0.05.
In all the figures, data are represented as mean ± standard deviation (SD).
3. Results and Discussion
3.1. X-ray Diffraction (XRD)
In Figure 1, the experimental pattern of the NPs is presented together with the theoretical diffraction
peaks of magnetite, (JCPDS card No. 19-0629) [38] showing that both, the location and relative intensity
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of Fe3O4@Al(OH)3 NPs coincide with the main theoretical 111, 220, 311, 400, 422, 511, 440 magnetite
reflections. This confirms that magnetite is the iron oxide crystalline phase present in the sample.
In addition, located at 20◦, a broadband which is overlapping with the (110) reflection of Fe3O4 can be
observed corresponding to the Al(OH)3 shell that can be ascribed to the amorphous boehmite phase
(JCPDS card No. 20-0011) [39,40].
Figure 1. X-ray diffraction (XRD) pattern of the core/shell structure of magnetite/aluminum hydroxide
nanoparticles, compared to the XRD pattern of magnetite from the JCPDS 19-0629 data base.
3.2. Fourier-Transform Infrared Spectroscopy (FTIR) Spectroscopy
Figure 2 shows the FT-IR spectra of Al(OH)3, Fe3O4@PAA, and Fe3O4@Al(OH)3 nanoparticles. The
peak observed around 550 cm−1 is characteristic of Fe-O vibrations [41], whereas the peaks at 1407, 2851,
and 2923 cm−1 are related to -CH2− groups, proving the presence of PAA in the sample. Furthermore, a
peak at 1701 cm−1 is also observed, related to the carboxyl group [42]. All these results reveal that the
surface of Fe3O4 NPs is successfully modified with PAA in the Fe3O4@PAA nanoparticles. The Al(OH)3
nanoparticles exhibit peaks at 510 and 1082 cm−1 that correspond to the Al-O bonds, which are also
observed in the Fe3O4@Al(OH)3 NPs. A large band around 3400 cm−1 is also observed, due to the -OH
groups adsorbed on the nanoparticle surface.
Figure 2. Fourier transform infrared (FTIR) spectra of aluminum hydroxide nanoparticles (NPs),
magnetite coated with polyacrylic acid NPs and polyacrylic acid magnetic nanoparticles coated with
aluminum hydroxide.
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3.3. Magnetic Characterization
Figure 3 show the magnetization curves versus the applied magnetic field from −10 kOe to
+10 kOe, measured on dried samples of Fe3O4@Al(OH)3 at room temperature with a Vibrating Sample
Magnetometer (VSM). Magnetization data were normalized to the amount of magnetite mass (Wmag)
for each sample (determined by FAAS), assuming all the iron present in the sample exists as Fe3O4,
and as it can be observed, the sample shows negligible coercive fields (Hc = 2.9 Oe) and remanence
(MR = 0.5 emu/g Fe3O4), corresponding to a nearly SPM NP behavior, characterized by an averaged
zero magnetic moment in the absence of an externally applied magnetic field. In addition, the saturation
magnetization of MNPsat = 62.8emu/gFe3O4, below the bulk magnetite value 92 emu/gFe3O4, is consistent
with a surface dead magnetic layer that lowers the total magnetization and is a characteristic signature
of its small size [43] (average crystallite size, Dhkl, is ca. 10 nm, as estimated from the XRD using the
Scherrer equation).
Figure 3. Magnetic hysteresis loop of a representative sample of Fe3O4@Al(OH)3 NPs, normalized to
the magnetite content and showing nearly superparamagnetic (SPM) behavior, with negligible values
of coercivity and remanence.
3.4. Transmission and Scanning Electron Microscopy (SEM, TEM, STEM, and EDS Mapping)
In Figure 4a, a TEM micrograph of Fe3O4@PAA precursor is shown, which was obtained from a
coprecipitation method, which was used to prepare the final Fe3O4@Al(OH)3 NPs. The magnetite cores
have an irregular spherical morphology with a medium size distribution of around 7 nm (Figure 4b).
Figure 4. (a) Transmission electron microscopy (TEM) micrograph and (b) size distribution of the
Fe3O4@PAA nanoparticles. The size distribution was performed by measuring a sample consisting of
486 magnetic nanoparticles with the ImageJ software.
SEM and TEM micrographs of Fe3O4@Al(OH)3 NPs (Figure 5) shows a nearly spherical morphology
with a diameter of around 200–250 nm, where magnetite cores (dark contrast) are embedded inside the
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nanostructure. It can be appreciated in the TEM image (Figure 5b) that the aluminum hydroxide phase
(light contrast) creates a wide and porous external layer, which helps in increasing the surface-to-volume
ratio of the NP allowing to incorporate a higher amount of the desired radiolabeling payload resulting
in great improvements in the detection capability.
Figure 5. Scanning electron microscopy (SEM) (a) and TEM (b) micrographs of the Fe3O4@Al(OH)3 NPs.
Additionally, a further assessment of the composition of the nanostructures was done by a
STEM-energy dispersive X-ray spectroscopy (EDX) mapping and presented in Figure 6. STEM micrograph
of the Fe3O4@Al(OH)3 NPs, is shown in Figure 6a and EDS mapping images of all the main constitutive
elements present in the samples, oxygen, O, (Figure 6b), iron, Fe, (Figure 6c), and aluminum, Al,
(Figure 6d) are homogeneously distributed. These results confirm the preliminary TEM assessment that
aluminum hydroxide has adequately coated the magnetite cores, being the nanostructure available for
both MRI/PET contrast activity.
Figure 6. (a) STEM micrograph and mapping with energy dispersive X-ray (EDX) emitted by the elements
present in the Fe3O4@Al(OH)3 samples: (b) oxygen, O (c) iron, Fe, (d) aluminum, Al, and (e) overlay of Fe
(purple color) and Al (green colour) signal.
3.5. Preliminary Study of Fluoride Adsorption of Non-Radioactive 19F−
Prior to the radiolabeling study of Fe3O4@Al(OH)3 NPs with 18F-sodium fluoride, a preliminary
assay of non-radioactive fluoride adsorption (19F) was performed in order to test the adsorption
capacity of the aluminum surface. It is well known that the solution’s pH of Al(OH)3 in a solvent has a
decisive influence on the adsorption potential of the adsorbent since it alters the adsorbent surface
charge [44,45]. It has been reported [46] that the fluoride ions adsorption ability of Fe3O4@Al(OH)3 NPs
is highly increased when using acid pH solutions, for this reason, a mixture (described in Section 2.2.6),
with pH 6.5 was selected for the present analysis.
In Figure 7, the equilibrium isotherm of fluoride adsorption is shown, for a set of 25 solutions
with pH 6.5 and increasing concentrations of fluoride ions (Ce/mg L−1) and its fitting to a Langmuir
adsorption model curve, which assumes a monolayer and homogeneous adsorption on a uniform
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adsorbent surface with energetically identical sorption sites where each molecules’ sorption energy is
the same with no interaction between the adsorbed ones [47,48]. Langmuir adsorption is described by





where qe (mg g−1) is the mass of fluoride adsorbed per mass of adsorbent, qm (mg g−1) is the Langmuir
constant correlated to the maximum capacity, KL (L mg−1) is the Langmuir constant related to the
energy of adsorption and Ce (mg L−1) is the concentration of fluoride at equilibrium.
Figure 7. Equilibrium isotherm of fluoride adsorption by Fe3O4@Al(OH)3 NPs at 25 ◦C, pH 6.5.
The regression coefficient (R2) was 0.999; this high R2 shows a high fit with the Langmuir equation.
The maximum adsorption capacity (qm) of fluoride was 194.03 mg/g Fe3O4@Al(OH)3 NPs, and the
Langmuir adsorption constant (KL) was 0.005 L/mg. This qm value indicates the high affinity of this
nanomaterial to adsorb fluoride as compared with previous work by Zhao et al. [46] and to be used for
radiolabeling with 18F-fluoride.
In addition, STEM-EDX mapping was performed on the fluoride loaded samples to assess the
distribution of the ions over the nanostructures. In Figure 8b, the presence of a high payload of fluoride
is observed homogeneously distributed over the Al(OH)3 surface.
Figure 8. (a) STEM micrograph and mapping with EDX emitted by the elements present in the fluoride
loaded Fe3O4@Al(OH)3 samples: (b) fluoride, F (c) iron, Fe, and (d) aluminum, Al.
3.6. Time Course and Stability of [18F]NaF complexation to Fe3O4@Al(OH)3 NPs
Next, NPs were labeled with 5–30 MBq radioactive [18F]NaF in Milli-Q water under constant
shaking. Small samples volumes were collected for iTLC in eluting chambers containing 0.9% NaCl
and subsequent analysis using either a gamma-counter or autoradiography (Figure 9).
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Figure 9. Time course of the radiolabeling of Fe3O4@Al(OH)3 NPs with [18F]F−. (A) Graphical
representation of the percentage of [18F]F− bound to NPs containing 1.34 mg/mL iron after two, five
or ten minutes of labeling with 5, 10, or 30 MBq [18F]NaF. No significant differences were found
between the different conditions (two-way repeated-measures ANOVA, Bonferroni correction), (B)
Representative autoradiography of iTLC of (left) NPs loaded with [18F]F− and (right) free [18F]NaF.
The retardation factor (Rf) of the labeled NPs indicates the complexation of the tracer to the NPs.
Two minutes after the addition of 5 MBq of the radiotracer, 98.68% of the NPs were labeled with
[18F]F−. The amount of bound [18F]F− did not change significantly over time (98.72% and 98.94% after
five and ten minutes, respectively; Figure 9A). Labeling the NPs with more radioactive 18F-fluoride
(up to 30 MBq) did not affect the radiolabeling significantly (Figure 9A). Similar percentages of bound
[18F]F− were achieved. Performing autoradiography on the iTLC papers confirmed the results obtained
by the gamma-counter as the retardation factor (Rf) of the radiolabeled NPs is zero. In contrast, free
[18F]NaF has an Rf of 1 (Figure 9B). Based on these results, we opted to radiolabel the NPs for ten
minutes for all subsequent experiments.
As the radiolabeled NPs are meant for future cell and in vivo experiments, the stability of the
adsorption of [18F]F− to the NPs was investigated in different physiological media. Hereby, samples
were collected after different times of exposure to the media and the [18F]F− content in the NP was
determined (Table 1). In a second experiment, NPs were resuspended in fresh media after each incubation
and centrifugation steps (Supplementary Table S1). While the radiolabeling was relatively stable in
Milli-Q water and saline, a steep decrease in the amount of [18F]F− adsorbed to the NPs was seen already
after 30 min after their submersion in PBS, cell culture medium for mMSCs, a mixture of 50% FBS, and
50% mMSCs medium or 100% FBS (Table 1). Most 18F release is associated with phosphate-containing
media. Interestingly, loss of fluoride ions occurs within the first 30 min with only limited additional
release during the following 4 h. Interestingly, repeated exposure to fresh media after each washing step
and continued incubation did not result in similarly large drops in fluoride content (Supplementary
Table S1).
Table 1. Stability of [18F]F− adsorption to Fe3O4@Al(OH)3 NPs after continued exposure to different media.
[18F]F− Bound to NPs after Storage at 37 ◦C for
30 min 1 h 2 h 4 h
% SD % SD % SD % SD
Milli-Q water 65.6 17.2 85.6 5.2 77.9 6.3 86.7 8.3
Saline 69.5 2.6 66.8 12.9 78.5 12.7 76.9 12.4
PBS 57.4 5.6 53.8 12.7 38.5 2.1 40.1 5.0
TrypLE 53.1 5.7 61.1 19.6 38.2 5.1 36.9 3.4
mMSC medium 40.4 7.9 46.9 7.4 38.3 8.9 28.9 1.7
50% medium/ 50% FBS 36.8 3.3 58.5 14.8 40.3 3.2 40.4 5.2
FBS 35.7 1.8 46.5 8.1 32.5 3.3 34.4 10.3
Three replicates were measured per condition. No significant differences were found between the different time
points based on a two-way repeated-measures ANOVA with Bonferroni correction for multiple comparisons.
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3.7. PET/MRI Visualization of Fe3O4@Al(OH)3 NPs and NP-Loaded mMSC Labelled with [18F]NaF
The potential of the nanostructures as imaging and cell tracking agent was evaluated in a phantom,
mimicking the conditions in the human body. Low amounts of radiolabeled NPs (0.048 mM iron,
labeled with 2 MBq [18F]F−) and cells labeled with NPs (12,500 mMSCs containing 1.48 × 10−3 mM iron
and labeled with approximately 0.05 MBq [18F]F−) could be visualized using simultaneously acquired
PET/MRI (Figure 10A).
Figure 10. PET/MRI contrast properties of Fe3O4@Al(OH)3 NPs labeled with [18F]F- and mouse
mesenchymal stem cells (mMSCs) labeled with such NPs: (A) Upper row: The different conditions
measured with the estimated radioactivity present at the start of measurements. Samples (100 µL) were
diluted 12 with agar. Middle:
18F-positron emission tomography (PET) images and Bottom: T2 maps
of the agar phantoms loaded with either radiolabeled Fe3O4@Al(OH)3 NPs (left) or mMSCs labeled
with radiolabeled Fe3O4@Al(OH)3 NPs (right). (B,C) Relaxation rate (R1/2/2*) plotted against (B) iron
concentration (mM) of Fe3O4@Al(OH)3 NPs or (C) intracellular iron concentration (mM) of mMSCs
labeled with different amounts of radiolabeled Fe3O4@Al(OH)3 NPs. The following cell densities
were studied: 12,500, 25,000, and 50,000 cells in 200 µL: 62,500 cells/mL, 125,000 cells/mL, and 250,000
cells/mL, respectively. The intracellular iron concentrations were obtained for 50,000 labeled cells.
The following relaxivities (rx) were obtained for the NPs: r2* = 468.8 ± 40.5 mM-1 s−1 (R2 = 0.93),
r2 = 83.6 ± 4.5 mM−1 s−1 (R2 = 0.97), and r1 = NPs: 0.2 ± 0.04 mM−1 s−1 (R2 = 0.74). These were
comparable or better than r2 values of other commercial contrast agents (Resovist) or experimental
iron oxide NPs [23,50,51] (Figure 10B). Also, r2* was much higher compared to Resovist. As expected,
T2/T2* values of labeled cells decreased with increasing cell numbers (Figure 10C). Even though the
intracellular environment results in release of some 18F-fluoride from the NPs, the radiolabel was still
suitable for mMSC visualization by PET. The count rates correlated with number of free NPs (iron
content; R2 = 0.99) and number of cells, respectively (R2 = 0.98; Supplementary Figure S1).
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In a preliminary proof-of-principle experiment, 105 mMSCs labeled with RL NPs (10.51 pg ±
1.43 pg Fe per cell and 1.9 MBq [18F]F−) were injected intravenously in a wild-type C57Bl/6 mouse
(see Supplementary Materials). We were able to visualize the uptake of the labeled cells/NPs in vivo,
in the lungs and liver using PET/MRI, indicating the feasibility of this technique to detect the mMSCs
(Supplementary Figure S2).
3.8. Assessment of Potentially Toxic Effects by Fe3O4@Al(OH)3 NPs
Cell survival was assessed after a 12 h exposure of MSC to different concentrations of Fe3O4@Al(OH)3
NPs. No significant changes were noticed compared to the unlabeled cells for concentrations of up to
100 µg mL−1 NPs (Figure 11A). Cell proliferation was assessed at two and six days after the removal of
NPs from the cell culture medium by determining population doubling times. Significant differences
compared to unlabeled MSCs were only seen for 250 µg NPs mL−1 at two days after removal of the NPs
from the medium (Figure 11B).
Figure 11. (A) Cell viability relative to the unlabeled control MSC was determined 12 h after exposure to
Fe3O4@Al(OH)3 NPs post-labeling: A significant reduction in the cell survival was seen for concentrations
> 100 µg NP mL−1. (B) Population doubling times (PDT) were determined after exposure of MSC to NPs
for 12 h and subsequent incubation in NP-free medium for two days (solid bares) and six days (striped
bares). Significant differences with respect to PDTs were only seen for concentrations of 250 µg NP mL−1
at two days after the removal of NPs from the medium. Three replicates were measured per condition.
Differences relative to unlabeled cells were assessed based on a one-way ANOVA with Bonferroni
correction. * p < 0.05 and *** p < 0.001.
4. Discussion
We were able to demonstrate that Fe3O4@Al(OH)3 NPs are suitable contrast agents for PET and
MR imaging. This provides the opportunity to overcome current limitations of PET (low resolution,
limited half-life of radiotracers) and MRI (lower sensitivity, difficulty to visualize NPs in areas of
low intrinsic signal intensity, for example lungs). This is in particular of interest for applications in
cell tracking, like the monitoring of stem cell therapy, cell transplantation, or immunotherapeutic
approaches [52–57].
In a first proof-of-concept study, we used Fe3O4@Al(OH)3 NPs for the labeling and tracking of
mMSCs. As the working mechanism and the optimal route of administration of MSCs is still unknown
and under debate [58], in vivo imaging and longitudinal tracking could help in understanding how
they function under in vivo conditions.
Characterization of our nanoparticles indicated high relaxivity even after cell labeling and
engraftment of the cells in mice. In terms of adsorption of the PET tracer [18F]NaF, two minutes
after the addition of 5 MBq of the radiotracer, 98.68% of the NPs were labeled with [18F]F−, which is
comparable to previous work by Cui and colleagues [23,59].
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The label remained stable in water. The addition of phosphates to the media clearly decreases the
amount of [18F]F− associated with the NPs starting from the initial measurement at 30 min. A possible
explanation is the loss of the Al(OH)3 from the NPs and the competition between the fluoride and
phosphate ions to bind to the Al(OH)3 shell of the NPs [23,59,60].
The steepest decrease at this early time point can be seen once the FBS medium is added. Even
though the composition of the serum used is unknown, the potential presence of citrate, a known
competitor for 18F-binding to Al(OH)3, could explain this very large drop in binding at early time
points [8]. However, after the initial loss of fluoride ions from the NPs the loading remained stable
over time, providing sufficient activity of the visualization of NPs and labeled cells. From the two
possible explanations for the initial loss of fluoride ions from the NPs: (1) Adjustment to an equilibrium
distribution bound/unbound [18F]F or (2) The maximum load of fluoride ions is exceeded by the initial
load; the second explanation is supported by our data (Supplementary Figure S1), indicating that the
initial ‘loss’ of radiolabel is most likely due to exposure to concentrations above loading capacity as the
further ‘dilution’ of labeled nanoparticles results in only small additional loss of fluoride label.
The PAA coating of the NPs provided good biocompatibility in the concentration ranged used in
our preliminary study. No indications of cell toxicity were seen for concentrations of up to 100 µg NP
per mL of cell culture medium.
Phantom experiments and cell labeling experiments focused on the visualization of mMSCs by
using PET/MRI. Despite some in vitro loss of label, as shown in the stability tests, we were able to
detect cells both in phantoms and in the mouse. In the preliminary mouse experiment, we chose to
inject the RL NP-labelled cells intravenously as this method is also often used to study the mechanism
of stem cells in cell therapy models [58,61,62]. The ability to visualize the labelled MSCs in vivo is
encouraging for future biodistribution studies of disease models. Combining PET and MRI would
open the opportunity for short-term follow-up and quantification of labelled cells with high specificity
(PET) and long-term monitoring of the NP-labelled cells with high resolution (MRI) [63,64].
Utilization of [18F]F− as a PET tracer has the disadvantage of a short half-life (110 min). But,
compared to other tracers like 89Zr, advantages include a higher beta branching ratio, a higher volume
sensitivity, and a lower partial volume effect, allowing better localization of the NPs [65,66].
Compared to the work of Cui et al. [23], the here presented nanomaterial shows a well-defined
core/shell structure (see morphologic characterization, Figure 5) through controlled hydrolysis of
aluminum hydroxide layer precursor salts ((Al(NO3)3·9H2O and Al2(SO4)3·16H2O). Our method
to obtain hydrophilic Fe3O4@Al(OH)3 NPs provides advantages which are the employment of
biocompatible and non-toxic starting reagents ((FeCl3·6H2O, FeSO4·7H2O, PAA and water as solvent)),
efficient material production, highly reproducible and cost-effective procedures (synthesis reaction
temperature <100 ◦C). Summarized, this can be understood as a great interest from the scientific and
industrial point of view.
In contrast to the serial acquisition of PET and MR images [22], a simultaneous PET/MRI approach
was applied in this study. This will provide not only spatial, but also temporal co-registration of PET
and MR images. In addition, the acquisition time will be reduced [67,68]. These advantages allow future
in vivo studies to focus on the validation of these NPs as cell tracking agents for longitudinal monitoring.
5. Conclusions
Efficient Fe3O4@Al(OH)3 NPs with controlled morphology were synthesized in situ by forced
chemical hydrolysis method, characterized and applied as a novel contrast agent for MRI and PET
imaging. Phantom studies of labeled NPs and mMSCs verified the high potential of these nanostructures
to adsorb radioactive fluoride in aqueous solutions. In addition, these radiolabeled NPs and labeled
mMSCs have excellent magnetic properties as superparamagnetic agents as well as good retention
of [18F]F− for visualization by MRI and PET, respectively. Furthermore, a simultaneous PET/MRI
approach allowed the visualization of radiolabeled cells in a preliminary in vivo study. Further research
will focus on the validation of these nanostructures as cell tracking agents.
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a healthy mouse injected with mouse mesenchymal stem cells (mMSCs) labeled with 18F-labeled Fe3O4@Al(OH)3
NPs, Table S1: Stability of [18F]F- adsorption to Fe3O4@Al(OH)3 nanoparticles (NPs) after repeated suspension of
NPs in fresh media after each incubation and centrifugation step.
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Abbreviations
ATR attenuated total reflectance
CT computed tomography
DMEM Dulbecco’s Modified Eagle’s Medium
ECA elemental chemical analysis
EDS energy dispersive X-ray spectroscopy
EDX energy dispersive X-ray
FAAS flame atomic absorption spectroscopy
FBS fetal bovine serum
Fe3O4@OA magnetite functionalized with oleic acid
FOV field of view
FTIR Fourier-Transform Infrared Spectroscopy
GOT glutamate oxaloacetate transaminase enzyme
GPT glutamate pyruvate transaminase enzyme
HMMSN Hybrid Magnetic Mesoporous Silica Nanorods
HAADF High-Angle Annular Dark Field
ICP-OES inductively coupled plasma optical emission spectroscopy
ISE Ion-Selective electrode
iTLC instant thin layer chromatography
(m)MSCs (mouse) mesenchymal stem cells
MNPs magnetic nanoparticles
MRI Magnetic Resonance Imaging
NPs nanoparticles
PBS Phosphate buffered saline
PDT population doubling times





SEM scanning electron microscopy
SPECT single photon emission computed tomography
SPM superparamagnetic
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STEM scanning transmission electron microscopy
SUV standardized uptake value
TGA Thermogravimetric analysis
TEM transmission electron microscopy
TISAB III Total Ionic Strength Adjustment Buffer solution
VSM vibrating sample magnetometer
XRD X-ray diffraction.
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